Tourmaline Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tourmaline Bio, Inc. - overview
Established
2002
Location
New York, NY, US
Primary Industry
Biotechnology
About
Based in New York, US, and founded in 2021, Tourmaline Bio, Inc. operates a biotechnology company that focuses on developing medicines for life-altering immune diseases. The company was co-founded by Sandeep Kulkarni, MD (CEO), and Caley Castelein, MD. In January 2024, Tourmaline Bio, Inc.
raised USD 150 million in a private placement, selling 4. 62 million shares at USD 32. 50 per share on the Nasdaq Global Select Market. The company's primary focus lies in the development of Tourmaline's anti-IL-6 antibody (TOUR006) for the treatment of thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD).
Its portfolio includes medications designed to address immune diseases that can have a profound impact on individuals, providing medical professionals with effective solutions to help cure their patients.
Current Investors
Kearny Venture Partners, QVT Financial, Petrichor
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.tourmalinebio.com/
Company Stage
Merged
Total Amount Raised
Subscriber access only
Tourmaline Bio, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Placement/Follow on | Completed | Tourmaline Bio, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.